摘要
目的探讨TKI药物对非小细胞肺腺癌的临床治疗效果。方法选取非小细胞肺腺癌患者100例,分为两组,使其有可比性。对其临床资料进行回顾分析。观察组患者采取吉非替尼治疗,对照组除不使用吉非替尼外所有治疗均同观察组。对两组患者治疗前后肿瘤大小进行比较,对观察组患者的临床效果进行统计,并记录不良反应发生情况。结果经过治疗,两组患者肿瘤均缩小,其中观察组缩小更为明显。观察组患者随访40个月,死亡31例,中位生存期16.73个月;生存期超过1年者28例(56.00%),35例(70.00%)患者疾病进展或者出现死亡,中位无疾病进展时间12.63个月;16例(32.00%)患者达到部分缓解,中位缓解期11.37个月;20例(40.00%)患者稳定,10例(20.00%)患者进展,还有4例(8.00%)患者疗效未能作出评价。除4例疗效未能作出评价的患者外其余46例患者在接受吉非替尼治疗过程中,其临床疗效受患者年龄、是否吸烟、有无皮疹以及呼吸困难是否加重等因素影响。皮疹是吉非替尼治疗后最常见的不良反应,其次是腹泻,各种不良反应均以Ⅰ度为主,Ⅱ度和Ⅲ度很少。结论吉非替尼作为TKI的代表性药物,在治疗非小细胞肺腺癌方面有确切效果,可以延长患者的生存期,而且不良反应少,容易在临床进行推广。
Objective To evaluate the clinical effect of TKI drug on nonsmall cell lung cancer .Methods Ana-lyzed the clinical data of 100 patients with non-small cell lung cancer .Observation group were treated by gefitinib tab-let ,the treatment of control group was same as observation group except without the gefitinib tablet .Compared with the tumor size ,clinical effect and adverse reactions .Results Observation group patients were followed up for 40 months .Thirty-one died ,the median survival time was 16 .73 months;28 patients （56 .00% ） survived more than 1 years ,35 cases（70 .00% ）with disease progression or death occurred ,the median time to progression free was 12 .63 months;16 patients（32 .00% ） achieved a partial response ,the median time was 11 .37 months ;20 patients（40 .00% ） were in the stable period ,10 patients（20 .00% ） were in progressed time .4 cases（8 .00% ） failed to evaluate .Clinical effect of 46 patients treated by gefitinib tablet was influenced by age ,smoking ,skin rashes and suffering breathing heavier and other factors .The rash was the most common adverse reactions ,followed by diarrhea .A variety of ad-verse reactions were Ⅰdegree ,Ⅱ and Ⅲ degree were rarely .Conclusion Gefitinib as the representative of TKI drugs in the treatment of non small cell lung cancer has exact effect ,which could extend the survival of patients with fewer adverse reactions ,and can be popularized easily in clinical .
出处
《检验医学与临床》
CAS
2013年第24期3268-3269,3272,共3页
Laboratory Medicine and Clinic
